EDX Medical Group PLC New partnership to provide testicular cancer tests

RNS Number : 0488L

EDX Medical Group PLC

06 November 2024

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

06 November  2024

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Company")

 

EDX MEDICAL SIGNS EXCLUSIVE PARTNERSHIP AGREEMENT

TO PROVIDE ADVANCED TESTICULAR CANCER TEST

 

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with mir|detect GmbH ("mir|detect") to distribute its M371 testicular cancer diagnostic test in the UK and Nordic markets.

 

The M371-Test is a simple blood test that enables highly accurate detection of critical biomarkers of testicular cancer in its early stages, the most common form of cancer among young men. More than 20,000 new cases are diagnosed each year in Europe. The test provides a highly reliable and cost-effective test solution which detects recurrences during the follow-up monitoring of patients with 100% sensitivity.  In the UK alone, there are 50,000 survivors of testicular cancer who may benefit from post-diagnosis monitoring.

 

The agreement between EDX Medical and mir|detect covers the UK, Sweden, Finland, Norway and Denmark.

 

Professor Sir Chris Evans, OBE, founder of EDX Medical Group plc, commented: "We are delighted to be partnering with mir|detect to increase patient's access to this marvellous test which is clearly outstanding when compared with previous tests for this type of cancer. This test is an excellent addition to our rapidly growing portfolio of class-leading diagnostic solutions."

 

Dr Mike Hudson, CEO, EDX Medical Group plc, said: "We are very pleased to be appointed as the exclusive distributor of the M371-Test in several countries, which is an excellent fit with our range of diagnostics which enable healthcare professionals to personalise and optimise treatment decisions for all patients. EDX Medical expects to continue to work with mir|detect in future to further refine and develop the test and associated services."

 

Dr Nina Winter, CEO, mir|detect commented: "The M371-Test provides faster and more reliable diagnosis of testicular germ cell tumours. It is minimally invasive, patient friendly and has a very high and reliable detection of recurrence in patients. We are delighted to have established our new relationship with EDX Medical."

 

The Board of directors of EDX Medical plc accepts responsibility for this announcement.

 

 Contacts:

 

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith   Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]
IFC Advisory (Investor Relations) Tim Metcalfe Graham Herring	[phone]

 

 

Notes for Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

www.edxmedical.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXZZMGMKKZGDZM